|
1
|
Martinez FJ, Collard HR, Pardo A, Raghu G,
Richeldi L, Selman M, Swigris JJ, Taniguchi H and Wells AU:
Idiopathic pulmonary fibrosis. Nat Rev Dis Primers.
3(17074)2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Lederer DJ and Martinez FJ: Idiopathic
pulmonary fibrosis. N Engl J Med. 378:1811–1823. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Burgstaller G, Oehrle B, Gerckens M, White
ES, Schiller HB and Eickelberg O: The instructive extracellular
matrix of the lung: Basic composition and alterations in chronic
lung disease. Eur Respir J. 50(1601805)2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Wynn TA: Integrating mechanisms of
pulmonary fibrosis. J Exp Med. 208:1339–1350. 2011.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Hutchinson J, Fogarty A, Hubbard R and
McKeever T: Global incidence and mortality of idiopathic pulmonary
fibrosis: A systematic review. Eur Respir J. 46:795–806.
2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Chanda D, Otoupalova E, Smith SR,
Volckaert T, De Langhe SP and Thannickal VJ: Developmental pathways
in the pathogenesis of lung fibrosis. Mol Aspects Med. 65:56–69.
2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Canestaro WJ, Forrester SH, Raghu G, Ho L
and Devine BE: Drug treatment of idiopathic pulmonary fibrosis:
Systematic review and network meta-analysis. Chest. 149:756–766.
2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Drakopanagiotakis F, Wujak L, Wygrecka M
and Markart P: Biomarkers in idiopathic pulmonary fibrosis. Matrix
Biol. 68-69:404–421. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
da Silva Antunes R, Mehta AK, Madge L,
Tocker J and Croft M: TNFSF14 (LIGHT) exhibits inflammatory
activities in lung fibroblasts complementary to IL-13 and TGF-β.
Front Immunol. 9(576)2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Heukels P, Moor CC, von der Thüsen JH,
Wijsenbeek MS and Kool M: Inflammation and immunity in IPF
pathogenesis and treatment. Respir Med. 147:79–91. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Zhang J, Wang D, Wang L, Wang S, Roden AC,
Zhao H, Li X, Prakash YS, Matteson EL, Tschumperlin DJ and Vassallo
R: Profibrotic effect of IL-17A and elevated IL-17RA in idiopathic
pulmonary fibrosis and rheumatoid arthritis-associated lung disease
support a direct role for IL-17A/IL-17RA in human fibrotic
interstitial lung disease. Am J Physiol Lung Cell Mol Physiol.
316:L487–L497. 2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Penke LR and Peters-Golden M: Molecular
determinants of mesenchymal cell activation in fibroproliferative
diseases. Cell Mol Life Sci. 76:4179–4201. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ballester B, Milara J and Cortijo J:
Idiopathic pulmonary fibrosis and lung cancer: Mechanisms and
molecular targets. Int J Mol Sci. 20(593)2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Rogliani P, Calzetta L, Cavalli F, Matera
MG and Cazzola M: Pirfenidone, nintedanib and N-acetylcysteine for
the treatment of idiopathic pulmonary fibrosis: A systematic review
and meta-analysis. Pulm Pharmacol Ther. 40:95–103. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Galli JA, Pandya A, Vega-Olivo M, Dass C,
Zhao H and Criner GJ: Pirfenidone and nintedanib for pulmonary
fibrosis in clinical practice: Tolerability and adverse drug
reactions. Respirology. 22:1171–1178. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Oldham JM, Ma SF, Martinez FJ, Anstrom KJ,
Raghu G, Schwartz DA, Valenzi E, Witt L, Lee C, Vij R, et al:
TOLLIP, MUC5B, and the response to N-Acetylcysteine among
individuals with idiopathic pulmonary fibrosis. Am J Respir Crit
Care Med. 192:1475–1482. 2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Li LC and Kan LD: Traditional Chinese
medicine for pulmonary fibrosis therapy: Progress and future
prospects. J Ethnopharmacol. 198:45–63. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Feng F, Wang Z, Li R, Wu Q, Gu C, Xu Y,
Peng W, Han D, Zhou X, Wu J and He H: Citrus alkaline extracts
prevent fibroblast senescence to ameliorate pulmonary fibrosis via
activation of COX-2. Biomed Pharmacother.
112(108669)2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Yu Y, Sun Z, Shi L, Zhang Y, Zhou Z, Zhang
S and Chao E: Effects of Feiwei granules in the treatment of
idiopathic pulmonary fibrosis: A randomized and placebo-controlled
trial. J Tradit Chin Med. 36:427–433. 2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Chen MJ, Yang GL, Ding YX and Tong ZQ:
Efficacy of TCM therapy of tonifying lung-kidney's Qi-deficiency in
a case of idiopathic pulmonary fibrosis: A case report. Medicine
(Baltimore). 98(e15140)2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Chen F, Wang PL, Fan XS, Yu JH, Zhu Y and
Zhu ZH: Effect of Renshen Pingfei Decoction, a traditional Chinese
prescription, on IPF induced by Bleomycin in rats and regulation of
TGF-β1/Smad3. J Ethnopharmacol. 186:289–297. 2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Giri SN, Hyde DM, Braun RK, Gaarde W,
Harper JR and Pierschbacher MD: Antifibrotic effect of decorin in a
bleomycin hamster model of lung fibrosis. Biochem Pharmacol.
54:1205–1216. 1997.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Laferriere CA and Pang DS: Review of
intraperitoneal injection of sodium pentobarbital as a method of
Euthanasia in laboratory Rodents. J Am Assoc Lab Anim Sci.
59:254–263. 2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wang Z, Feng F, Wu Q, Gu C, Xu Y and Zhou
X: Comparison of three methods to establish a mouse model of
pulmonary fibrosis induced by intratracheal instillation of
bleomycin. Chinese Journal of Comparative Medicine. 29:51–57.
2019.(In Chinese).
|
|
25
|
Hotham WE and Henson FMD: The use of large
animals to facilitate the process of MSC going from laboratory to
patient-ʻbench to bedside’. Cell Biol Toxicol. 36:103–114.
2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Szapiel SV, Elson NA, Fulmer JD,
Hunninghake GW and Crystal RG: Bleomycin-induced interstitial
pulmonary disease in the nude, athymic mouse. Am Rev Respir Dis.
120:893–899. 1979.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Hübner RH, Gitter W, El Mokhtari NE,
Mathiak M, Both M, Bolte H, Freitag-Wolf S and Bewig B:
Standardized quantification of pulmonary fibrosis in histological
samples. Biotechniques. 44:507-511:514–517. 2008.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Surolia R, Li FJ, Wang Z, Li H, Dsouza K,
Thomas V, Mirov S, Pérez-Sala D, Athar M, Thannickal VJ and Antony
VB: Vimentin intermediate filament assembly regulates fibroblast
invasion in fibrogenic lung injury. JCI Insight.
4(e123253)2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Zhou Y, Tong X, Ren S, Wang X, Chen J, Mu
Y, Sun M, Chen G, Zhang H and Liu P: Synergistic anti-liver
fibrosis actions of total astragalus saponins and glycyrrhizic acid
via TGF-β1/Smads signaling pathway modulation. J Ethnopharmacol.
190:83–90. 2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Li Q, Hu L, Zhao Z, Ma L, Li J, Xu L and
Wang J: Serum changes in pyridinoline, type II collagen cleavage
neoepitope and osteocalcin in early stage male brucellosis
patients. Sci Rep. 10(17190)2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Sun YB, Qu X, Caruana G and Li J: The
origin of renal fibroblasts/myofibroblasts and the signals that
trigger fibrosis. Differentiation. 92:102–107. 2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Zheng X, Qi C, Zhang S, Fang Y and Ning W:
TGF-β1 induces Fstl1 via the Smad3-c-Jun pathway in lung
fibroblasts. Am J Physiol Lung Cell Mol Physiol. 313:L240–L251.
2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Epstein Shochet G, Brook E, Israeli-Shani
L, Edelstein E and Shitrit D: Fibroblast paracrine TNF-α signaling
elevates integrin A5 expression in idiopathic pulmonary fibrosis
(IPF). Respir Res. 18(122)2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Epstein Shochet G, Brook E,
Bardenstein-Wald B and Shitrit D: TGF-β pathway activation by
idiopathic pulmonary fibrosis (IPF) fibroblast derived soluble
factors is mediated by IL-6 trans-signaling. Respir Res.
21(56)2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Gao Y, Yao LF, Zhao Y, Wei LM, Guo P, Yu
M, Cao B, Li T, Chen H and Zou ZM: The Chinese herbal medicine
formula mKG suppresses pulmonary fibrosis of mice induced by
bleomycin. Int J Mol Sci. 17(238)2016.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Malaviya R, Laskin JD and Laskin DL:
Anti-TNFalpha therapy in inflammatory lung diseases. Pharmacol
Ther. 180:90–98. 2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Yang D, Chen X, Wang J, Lou Q, Lou Y, Li
L, Wang H, Chen J, Wu M, Song X and Qian Y: Dysregulated lung
commensal bacteria drive interleukin-17B production to promote
pulmonary fibrosis through their outer membrane vesicles. Immunity.
50:692–706.e7. 2019.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Papiris SA, Tomos IP, Karakatsani A,
Spathis A, Korbila I, Analitis A, Kolilekas L, Kagouridis K,
Loukides S, Karakitsos P and Manali ED: High levels of IL-6 and
IL-8 characterize early-on idiopathic pulmonary fibrosis acute
exacerbations. Cytokine. 102:168–172. 2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Barratt SL, Creamer A, Hayton C and
Chaudhuri N: Idiopathic pulmonary fibrosis (IPF): An overview. J
Clin Med. 7(201)2018.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Sharif R: Overview of idiopathic pulmonary
fibrosis (IPF) and evidence-based guidelines. Am J Manag Care. 23
(Suppl 11):S176–S182. 2017.PubMed/NCBI
|
|
42
|
Saito S, Alkhatib A, Kolls JK, Kondoh Y
and Lasky JA: Pharmacotherapy and adjunctive treatment for
idiopathic pulmonary fibrosis (IPF). J Thorac Dis. 11 (Suppl
14):S1740–S1754. 2019.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Herrera J, Forster C, Pengo T, Montero A,
Swift J, Schwartz MA, Henke CA and Bitterman PB: Registration of
the extracellular matrix components constituting the fibroblastic
focus in idiopathic pulmonary fibrosis. JCI Insight.
4(e125185)2019.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Shigemura Y, Iwasaki Y, Tateno M, Suzuki
A, Kurokawa M, Sato Y and Sato K: A pilot study for the detection
of cyclic prolyl-hydroxyproline (Pro-Hyp) in human blood after
ingestion of collagen hydrolysate. Nutrients.
10(1356)2018.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Zhu Y, Zheng X, Wang C, Sun X, Sun H, Ma
T, Li Y, Liu K, Chen L and Ma X: Synthesis and biological activity
of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the
treatment of idiopathic pulmonary fibrosis. Bioorg Med Chem.
28(115254)2020.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Sgalla G, Iovene B, Calvello M, Ori M,
Varone F and Richeldi L: Idiopathic pulmonary fibrosis:
Pathogenesis and management. Respir Res. 19(32)2018.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Beringer A and Miossec P: IL-17 and TNF-α
co-operation contributes to the proinflammatory response of hepatic
stellate cells. Clin Exp Immunol. 198:111–120. 2019.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Lin J, Shi Y, Men Y, Wang X, Ye J and
Zhang C: Mechanical roles in formation of oriented collagen fibers.
Tissue Eng Part B Rev. 26:116–128. 2020.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Oike T, Kanagawa H, Sato Y, Kobayashi T,
Nakatsukasa H, Miyamoto K, Nakamura S, Kaneko Y, Kobayashi S,
Harato K, et al: IL-6, IL-17 and Stat3 are required for
auto-inflammatory syndrome development in mouse. Sci Rep.
8(15783)2018.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Lei L, Zhao C, Qin F, He ZY, Wang X and
Zhong XN: Th17 cells and IL-17 promote the skin and lung
inflammation and fibrosis process in a bleomycin-induced murine
model of systemic sclerosis. Clin Exp Rheumatol. 34 (Suppl
100):S14–S22. 2016.PubMed/NCBI
|
|
51
|
Wang YY, Jiang H, Pan J, Huang XR, Wang
YC, Huang HF, To KF, Nikolic-Paterson DJ, Lan HY and Chen JH:
Macrophage-to-myofibroblast transition contributes to interstitial
fibrosis in chronic renal allograft injury. J Am Soc Nephrol.
28:2053–2067. 2017.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Zhao W, Wang X, Sun KH and Zhou L:
α-smooth muscle actin is not a marker of fibrogenic cell activity
in skeletal muscle fibrosis. PLoS One. 13(e0191031)2018.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Ding D, Li C, Zhao T, Li D, Yang L and
Zhang B: LncRNA H19/miR-29b-3p/PGRN axis promoted
epithelial-mesenchymal transition of colorectal cancer cells by
acting on wnt signaling. Mol Cells. 41:423–435. 2018.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Schett G, Manger B, Simon D and Caporali
R: COVID-19 revisiting inflammatory pathways of arthritis. Nat Rev
Rheumatol. 16:465–470. 2020.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Saha P and Smith A: TNF-α (Tumor Necrosis
Factor-α). Arterioscler Thromb Vasc Biol. 38:2542–2543.
2018.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Rose-John S: Interleukin-6 family
cytokines. Cold Spring Harb Perspect Biol.
10(a028415)2018.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Cipolla E, Fisher AJ, Gu H, Mickler EA,
Agarwal M, Wilke CA, Kim KK, Moore BB and Vittal R: IL-17A
deficiency mitigates bleomycin-induced complement activation during
lung fibrosis. FASEB J. 31:5543–5556. 2017.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Zhou Z, Kandhare AD, Kandhare AA and
Bodhankar SL: Hesperidin ameliorates bleomycin-induced experimental
pulmonary fibrosis via inhibition of TGF-beta1/Smad3/AMPK and
IkappaBalpha/NF-kappaB pathways. EXCLI J. 18:723–745.
2019.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Guo J, Fang Y, Jiang F, Li L, Zhou H, Xu X
and Ning W: Neohesperidin inhibits TGF-β1/Smad3 signaling and
alleviates bleomycin-induced pulmonary fibrosis in mice. Eur J
Pharmacol. 864(172712)2019.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Geng XQ, Ma A, He JZ, Wang L, Jia YL, Shao
GY, Li M, Zhou H, Lin SQ, Ran JH and Yang BX: Ganoderic acid
hinders renal fibrosis via suppressing the TGF-β/Smad and MAPK
signaling pathways. Acta Pharmacol Sin. 41:670–677. 2020.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Kurundkar AR, Kurundkar D, Rangarajan S,
Locy ML, Zhou Y, Liu RM, Zmijewski J and Thannickal VJ: The
matricellular protein CCN1 enhances TGF-β1/SMAD3-dependent
profibrotic signaling in fibroblasts and contributes to fibrogenic
responses to lung injury. FASEB J. 30:2135–2150. 2016.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Shimbori C, Bellaye PS, Xia J, Gauldie J,
Ask K, Ramos C, Becerril C, Pardo A, Selman M and Kolb M:
Fibroblast growth factor-1 attenuates TGF-β1-induced lung fibrosis.
J Pathol. 240:197–210. 2016.PubMed/NCBI View Article : Google Scholar
|
